SEC Comment Letter 0000000000-23-008424 to Neptune Wellness Solutions Inc. (NEPTF) (CIK 0001401395)

Neptune Wellness Solutions Inc. (NEPTF) (CIK 0001401395)
Date: Aug. 4, 2023 · CIK: 0001401395 · Accession: 0000000000-23-008424

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-273545

Date

August 4, 2023

Author

Not clearly detected

Form

UPLOAD

Company

Neptune Wellness Solutions Inc. (NEPTF) (CIK 0001401395)

Letter

United States securities and exchange commission logo August 4, 2023 Raymond Silcock Chief Financial Officer Neptune Wellness Solutions Inc. 545 Promenade du Centropolis Suite 100 Laval, Quebec, Canada H7T 0A3 Re:Neptune Wellness Solutions Inc. Registration Statement on Form S-1 Filed July 31, 2023 File No. 333-273545 Dear Raymond Silcock: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Shona C. Smith, Esq.

Show Raw Text

United States securities and exchange commission logo
August 4, 2023
Raymond Silcock
Chief Financial Officer
Neptune Wellness Solutions Inc.
545 Promenade du Centropolis Suite 100
Laval, Quebec, Canada H7T 0A3
Re:Neptune Wellness Solutions Inc.
Registration Statement on Form S-1
Filed July 31, 2023
File No. 333-273545
Dear Raymond Silcock:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Shona C. Smith, Esq.

SecProbe.io